封面
市場調查報告書
商品編碼
1198723

血管閉合裝置 (VCD) 市場——增長、趨勢、COVID-19 的影響和預測 (2023-2028)

Vascular Closure Device (VCD) Market - Growth, Trends, and Forecasts (2023 - 2028)

出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

血管閉合裝置 (VCD) 市場預計在預測期內 (2022-2027) 的複合年增長率為 6.82%。

在 COVID-19 大流行期間,非緊急手術的減少影響了市場的增長。 根據 2021 年 12 月在 JAMA Network Open 上發表的文章“美國外科手術的趨勢和醫療保健系統對在 COVID-19 大流行期間限制選擇性外科手術的政策的反應”,大流行正在影響醫療護理,包括外科護理。他說影響了方方面面。 該論文分析了美國 2020 年 11 月至 2021 年 7 月的手術數據,指出 2020 年 3 月至 4 月的初始停工期與手術量的減少有關。 限制解除後,手術率已恢復到 2019 年的水平。 在 COVID-19 大流行期間,手術數量的這種下降阻礙了市場增長。

導管相關手術的增加、對微創解決方案的需求不斷增長以及 VCD 的易用性等因素,再加上心血管疾病負擔的增加,正在推動市場的增長。 越來越多的患者選擇微創球囊成形術,因為微創手術具有手術痛苦小、損傷小、疤痕小、住院時間短、準確性高、恢復快等幾個優點。 心血管疾病及其死亡率日益增加的負擔創造了對治療設備的需求,從而推動了市場增長。 例如,世界衛生組織 (WHO) 的一篇題為“心血管疾病”的文章。 2021 年 6 月更新的“關鍵事實”報告稱,心血管疾病 (CVD) 是全球死亡的主要原因。

此外,市場增長還受到新產品發布的推動。 例如,2021 年 9 月,Haemonetics Corporation 的 VASCADE MVP 靜脈血管閉合系統獲得了美國食品藥品監督管理局的批准。 因此,各種市場參與者產品的監管批准數量正在推動市場增長。 然而,產品的高成本和與 VCD 相關的複雜性可能會阻礙預測期內的市場增長。

血管閉合裝置 (VCD) 市場趨勢

預計在預測期內股骨通路部分將出現顯著增長

用於股動脈通路的血管閉合裝置是介入心髒病專家和其他程序專家在導管插入部位實現止血的有力工具。 證明股動脈血管閉合裝置好處的研究推動了這一細分市場的增長。 例如,“Comparison of MynxGrip vascular closure device and manual compression for closure after femoral access angiography: a randomized controlled trial: the closure devices used in everyday practice study, CLOSE-UP III”發表於 2022 年 2 月 BMC Cardiovascular Disorders 試驗”市場上兩種血管閉合裝置的安全性和有效性。 結果,兩者都得出結論,嚴重血管不良事件的發生很少見。 股骨通路血管閉合裝置的這些優點促進了它們的使用,從而促進了細分市場的增長。

此外,市場參與者之間在不同地區的設備營銷和商業化合作正在推動該細分市場的增長。 例如,2022 年 5 月,醫療技術提供商 Teleflex Incorporated 獲得了加拿大衛生部對 MANTA 血管閉合裝置的批准,這是第一款專為大直徑股動脈通路閉合而設計的商用生物力學血管閉合裝置。 MANTA 裝置適用於在血管內導管插入術中使用 10-20F 裝置或護套(12-25F 外徑)後,股動脈通路部位閉合,止血時間縮短。

在此背景下,市場有望在預測期內顯著增長。

北美佔據了市場的主要份額,預計在預測期內也會如此。

不斷增長的醫療基礎設施、不斷增加的心血管疾病負擔以及導管相關手術的增加,以及該國對微創解決方案不斷增長的需求正在推動該地區的市場增長。我來了。 根據疾病控制與預防中心 (CDC) 題為“心髒病事實”的文章,該文章於 2022 年 2 月更新,心髒病是美國的頭號死因。 另據報導,美國每年約有65.9萬人死於心髒病。 如此高的疾病負擔導致了對血管閉合裝置的需求,並正在推動該地區的市場增長。

此外,美國食品藥品監督管理局和加拿大衛生部等監管機構的批准也在推動市場增長。 例如,2021年4月,EnsiteVascular獲得美國食品藥品監督管理局(FDA)第二次批准,其SiteSeal SV(小血管)VCD加壓裝置可在經支氣管血管內治療後實現肱動脈止血,並獲得上市許可。 SiteSeal SV 是一種新型閉塞裝置,專為閉塞小動脈(尤其是肱動脈、橈動脈和足動脈)而設計。 模擬外部壓縮,但刪除相關變量,什麼也不留下。

2021 年 10 月,Haemonetics 還獲得了美國食品和藥物管理局的批准,可以在使用該公司的 Vascade MVP 靜脈血管閉合系統進行房顫消融後當天出院。 Vascade MVP 是一種血管閉合系統,適用於需要在多個通路部位進行靜脈閉合的手術。

因此,由於上述因素,預計在預測期內,北美地區的血管閉合裝置市場將出現顯著增長。

血管閉合裝置 (VCD) 市場競爭對手分析

由於競爭對手之間的激烈競爭,預計該市場將出現利潤豐厚的增長,從而導致該行業產生高收入。 這個市場的參與者正致力於開發新的 VCD 並擴展他們的產品組合。 通過與中小型公司的收購和合作夥伴關係增加影響力也將推動該行業的增長。 市場上的主要參與者是雅培實驗室、Cardinal Health Inc.、Biotronik SE &Co.KG、Cardinal Health Inc.、CardivaMedical Inc. 和 Terumo Corporation。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 增加導管相關手術
    • 對微創解決方案的需求增加
    • VCD 的可用性
  • 市場製約因素
    • 產品成本高
    • 與 VCD 相關的並發症
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分(按價值計算的市場規模:百萬美元)

  • 產品類型
    • 主動式加速度計
      • 剪輯設備
      • 使用縫線的裝置
      • 可插拔
    • 被動逼近器
      • 止血墊/貼片
      • 壓縮機
  • 如何訪問
    • 股骨入路
    • 徑向訪問
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Abbott Laboratories
    • Advanced Vascular Dynamics
    • B. Braun Melsungen AG
    • Biotronik SE & Co. KG
    • Becton, Dickinson and Company(C.R. Bard Inc.)
    • Cardinal Health Inc.
    • Cardiva Medical Inc.
    • Vivasure Medical Ltd
    • Medtronic PLC
    • Terumo Corporation

第7章 市場機會今後動向

簡介目錄
Product Code: 66042

The vascular closure device (VCD) market is anticipated to exhibit a CAGR of 6.82 % over the forecast period (2022-2027).

During the COVID-19 pandemic, there was a reduction in the non-emergency surgical procedure, which impacted the growth of the market. According to an article titled "Trends in US Surgical Procedures and Health Care System Response to Policies Curtailing Elective Surgical Operations During the COVID-19 Pandemic" published in the journal of JAMA Network Open in December 2021, the pandemic had affected every aspect of medical care, including the surgical treatments. The article analyzed the surgical data in the United States from November 2020 through July 2021 and indicated that the initial shutdown period in March 2020 through April 2020, was associated with a decrease in surgical procedure volumes. After the restrictions were lifted, the rate of surgical procedures rebounded to 2019 levels. Such reductions in the surgical volumes hindered the growth of the market during the COVID-19 pandemic.

Factors such as an increase in catheterization-related procedures, a rise in demand for minimally invasive solutions, and ease of usage of VCDs, coupled with the growing burden of cardiovascular diseases, are driving the growth of the market. The several advantages of minimally invasive surgeries, such as reduced surgical pain, injury, scarring, hospital stay, higher accuracy, and speedy recovery time, are encouraging an increasing number of patients to opt for minimally invasive balloon angioplasty surgeries. The growing burden of cardiovascular disease and deaths due to it generates the need for devices for the treatment and hence drives the market's growth. For instance, the World Health Organization article titled 'Cardiovascular Diseases: Key Facts' updated in June 2021, reported that cardiovascular diseases (CVDs) are the leading cause of death globally.

Additionally, the market growth is also propelled by the launch of new products. For instance, in September 2021, Haemonetics Corporation received the United States Food and Drug Administration's approval for VASCADE MVP Venous Vascular Closure System. Thus, the number of approvals by the regulatory authority for the products by different market players is boosting the growth of the market. However, the high cost of products and complications associated with VCDs may hinder the growth of the market over the forecast period.

Vascular Closure Device (VCD) Market Trends

Femoral Access Segment is Expected to Show Significant Growth Over the Forecast Period

Femoral vascular closure devices are powerful tools for interventional cardiologists and other proceduralists to achieve hemostasis at the catheterization entry site. The market segment growth is boosted by the research studies demonstrating the benefits of femoral vascular closure devices. For instance, an article titled "Comparison of MynxGrip vascular closure device and manual compression for closure after femoral access angiography: a randomized controlled trial: the closure devices used in everyday practice study, CLOSE-UP III trial" published in the journal of BMC Cardiovascular Disorders in February 2022 compared the safety and efficacy of two vascular closure devices available in the market. The study concluded that the occurrence of a major adverse vascular event was rare in both cases. Such benefits of the femoral access vascular closure devices promote their usage, hence driving the growth of the market segment.

Additionally, the collaboration among the market players for the marketing and commercialization of devices in different regions is driving the growth of the market segment. For Instance, in May 2022, Teleflex Incorporated, a medical technologies provider, received Health Canada approval for the MANTA Vascular Closure Device, the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure. MANTA Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20F devices or sheaths (12-25F OD) in endovascular catheterization procedures.

Thus, owing to the abovementioned factors, the market segment is expected to grow significantly over the forecast period.

North America Holds Major Share in the Market and is Expected to do the Same Over the Forecast Period.

The well-established healthcare infrastructure, the growing burden of cardiovascular diseases, coupled with an increase in catheterization-related procedures, and the rise in demand for minimally invasive solutions in the country are driving the growth of the market in the region. According to the Center for Disease Control and Prevention (CDC) article titled 'Heart Diseases Facts' updated in February 2022, heart disease is the leading cause of death in the United States. It also reported that about 659,000 people in the United States die from heart disease each year. Such a high burden of the disease generates the need for vascular closure devices and drives the growth of the market in the region.

Additionally, the market growth is also boosted by approval from regulatory authorities such as the United States Food and Drug Administration and Health Canada. For instance, in April 2021, EnsiteVascular received its second United States Food and Drug Administration (FDA) market clearance for the company's SiteSeal SV (small vessel) VCD compression device to achieve hemostasis of the brachial artery after a transbronchial endovascular procedure. SiteSeal SV is a new closure device designed for the closure of small arterial vessels, specifically brachial, radial and pedal. It simulates external compression, but removes the associated variables, leaving nothing behind.

Also, in October 2021, Haemonetics received approval from the United States Food and Drug Administration for same-day discharge after atrial fibrillation ablation using its Vascade MVP venous vascular closure system. Vascade MVP is a vascular closure system that is designed for procedures that require multiple access site venous closures.

Thus, owing to the abovementioned factors, the vascular closure device market is expected to project significant growth in the North American region over the forecast period.

Vascular Closure Device (VCD) Market Competitor Analysis

This market is expected to witness lucrative growth due to a high level of competitive rivalry, which translates to high revenue generation in this sector. The prominent players in this market are involved in developing novel VCDs and, in turn, broadening their product portfolios. Acquisition and collaboration with small companies to enhance presence are also expected to propel growth in this vertical. The major players in the market are Abbott Laboratories, Cardinal Health Inc., Biotronik SE & Co. KG, Cardinal Health Inc., CardivaMedical Inc., and Terumo Corporation.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Catheterization-related Procedures
    • 4.2.2 Increase in Demand for Minimally Invasive Solutions
    • 4.2.3 Ease of Use of VCDs
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Products
    • 4.3.2 Complications Associated with VCDs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 Product Type
    • 5.1.1 Active Approximators
      • 5.1.1.1 Clip-based Devices
      • 5.1.1.2 Suture-based Devices
      • 5.1.1.3 Plug-based Devices
    • 5.1.2 Passive Approximators
      • 5.1.2.1 Hemostatic Pads and Patches
      • 5.1.2.2 Compression Devices
  • 5.2 Mode of Access
    • 5.2.1 Femoral Access
    • 5.2.2 Radial Access
  • 5.3 End User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centres
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Advanced Vascular Dynamics
    • 6.1.3 B. Braun Melsungen AG
    • 6.1.4 Biotronik SE & Co. KG
    • 6.1.5 Becton, Dickinson and Company (C.R. Bard Inc.)
    • 6.1.6 Cardinal Health Inc.
    • 6.1.7 Cardiva Medical Inc.
    • 6.1.8 Vivasure Medical Ltd
    • 6.1.9 Medtronic PLC
    • 6.1.10 Terumo Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS